According to Agenus
's latest financial reports the company has a price-to-book ratio of -1.17.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2023-12-31 | -2.13 | -84.03% |
2022-12-31 | -13.3 | -177.19% |
2021-12-31 | 17.3 | -685.47% |
2020-12-31 | -2.95 | 21.6% |
2019-12-31 | -2.42 | 48.19% |
2018-12-31 | -1.64 | -62.02% |
2017-12-31 | -4.31 | -53.05% |
2016-12-31 | -9.17 | -265.44% |
2015-12-31 | 5.55 | -48.74% |
2014-12-31 | 10.8 | -150.51% |
2013-12-31 | -21.4 | 273.68% |
2012-12-31 | -5.73 | 178.21% |
2011-12-31 | -2.06 | -73.13% |
2010-12-31 | -7.67 | 126.53% |
2009-12-31 | -3.38 | 116.28% |
2008-12-31 | -1.56 | -24.09% |
2007-12-31 | -2.06 | -57.26% |
2006-12-31 | -4.82 | -170.9% |
2005-12-31 | 6.80 | 57.14% |
2004-12-31 | 4.33 | 1.66% |
2003-12-31 | 4.26 | -2.35% |
2002-12-31 | 4.36 |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | 5.20 | -544.19% | ๐บ๐ธ USA |
Merck MRK | 8.80 | -850.92% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | 3.36 | -386.65% | ๐บ๐ธ USA |
GlaxoSmithKline GSK | 5.13 | -537.96% | ๐ฌ๐ง UK |
Celldex Therapeutics CLDX | 5.67 | -583.69% | ๐บ๐ธ USA |